SAR443579 (also known as IPH6101) is a tri-functional NKp46/CD16-based anti-CD123 NK cell engager – described as a first-in-class therapy – that has now advanced into a phase 2 programme.

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the ...

Sanofi has moved its natural killer (NK) cell engager candidate SAR443579/IPH6101 to a Phase II trial evaluating the drug’s use in treating a range of blood cancers. The drugmaker dosed the ...